See 20-25% upside in Lupin, says TS Harihar

TS Harihar of HRBV Client Solutions told CNBC-TV18, "In Sun Pharmaceutical Industries, there could be some element of consolidation because they have just completed the acquisition of Ranbaxy Laboratories and the entire fit would take some more time."

"However as far as Lupin is concerned, I think their focus on generic has worked well and over the last two and a half to three years, the stock has appreciated about five times. Even at these prices, the stock continues to look fairly attractive. So from a very short-term perspective, it is slightly hard to say but if you give one quarter’s leeway, I would believe that Lupin would still have about 20-25 percent upside from these levels," he said.